



The 21th Congress on

INNOVATION IN REPRODUCTIVE MEDICINE

Improving our skills through education



Frankfurt, Germany | May 14-16, 2015

www.cogi.org | cogi@comtecmed.com

HONORARY CHAIRMAN

Diethelm Wallwiener, Germany

CONGRESS CHAIRPERSONS

Klaus Diedrich, Germany

Andreas Schmutzler, Germany

Zeev Shoham, Israel

ORGANIZING COMMITTEE

Christian De Geyter, Switzerland

Klaus Diedrich, Germany

Norbert Gleicher, USA

Ludwig Kiesel, Germany

Andreas Schmutzler, Germany

Zeev Shoham, Israel

Thomas Strowitzki, Germany

Seang Lin Tan, Canada

Gurkan Uncu, Turkey

Ariel Weissman, Israel

PRELIMINARY SCIENTIFIC PROGRAM

THURSDAY, MAY 14, 2015

THURSDAY, MAY 14, 2015	
14:30-16:00	SESSION 1: TIME- LAPSE TECHNOLOGY WHAT IS THE GOAL AND WHAT ARE THE DIFFERENCES BETWEEN THE TECHNOLOGIES?
	Laboratory aspects: Simon Fishel , UK Clinical aspects: Milton Leong , HK Dark field technology: Jon Aizpurua , Spain Pitfalls related to the technology: Norbert Gleicher , USA
16:00-16:30	Coffee Break
16:30-18:00	SESSION 2: DEBATE: NEW RECOMBINANT FSH ON THE MARKET: VIEWS FROM THE EXPERTS
	Molecular aspects and background: Hermann Allgaier , Germany Clinical perspective: Klaus Diedrich , Germany Supporting the current available recombinant FSH: Klaus Bühler , Germany
18:00-19:00	SESSION 3: ARE WE REACHING THE TIME WHEN SCIENCE MEETS WISHFUL THINKING?
	Autologous mitochondrial injection to increase energy in oocytes: Robert Casper , Canada Non-invasive prenatal diagnosis from the blood of pregnant women- finally available in clinical practice: Wolfgang Holzgreve , Germany

PRELIMINARY SCIENTIFIC PROGRAM (cont)

FRIDAY, MAY 15, 2015

FRIDAY, MAY 15, 2015	
HALL A	HALL B
08:30-10:30	SESSION 4A: NEW INNOVATION IN CRYOBIOLOGY
	<p>Debate: Social freezing of oocytes and ovarian tissue to maintain fertility and postpone menopause: low cost, easy administration and good outcome. Is it such? For: Claus Yding Andersen, Denmark Against: Michael von Wolff, Switzerland</p> <p>Pregnancies and live births after 20 transplantations of cryopreserved ovarian tissue: The technology is now available for all: Ralf Dittrich, Germany</p> <p>Oocyte cryopreservation for fertility preservation in cancer patients – how good is it? If you have one go and perhaps a reduced response due to sickness, what should be the stimulation protocol? Kenny Rodriguez-Wallberg, Sweden</p>
	<p>Individual preparation of the ovaries for PGD or PGS: Andreas Schmutzler, Germany</p> <p>Debate: Should PGS be offered to all IVF patients? Pro: Simon Fishel, UK Con: PGS: Norbert Gleicher, USA</p> <p>Polar body biopsy: new aspects: Luca Gianaroli, Italy How next-generation sequencing revolutionized reproductive medicine: Yuval Yaron, Israel</p>
10:30-11:00	<i>Coffee Break</i>
11:00-12:30	SESSION 5A: GETTING THE BEST PREGNANCY RATE: STIMULATION AND ET
	<p>IVF outcomes in patients with extremely poor prognosis: Ariel Weissman, Israel</p> <p>Superovulation protocol for poor responders: a new approach: Basil Tarlatzis, Greece</p> <p>Treating infertile premature ovarian insufficiency (POI) patients: ovarian fragmentation followed by Akt stimulation treatment in vitro and autotransplantation (in vitro activation – IVA): Kazuhiro Kawamura, Japan</p> <p>GnRH agonist triggering oocyte maturation for all ART cycles: Four years' experience and results: Robert Fischer, Germany</p>
	<p>Surgical therapy of deep infiltrating endometriosis: state of the art and limitations: Bernhard Krämer, Germany</p> <p>Adenomyosis: a neglected disease? Florin-Andrei Taran, Germany</p> <p>Live streaming of 2 surgical procedures on endometrioses: Ralf Rothmund, Germany Diethelm Wallwiener, Germany</p>
12:30-13:30	<i>Lunch Break</i>
13:30-15:30	SESSION 6A: GETTING THE BEST PREGNANCY RATE: STIMULATION AND ET (2)
	<p>Debate: Neoadjuvants in stimulation protocols: what can we add For: Gürkan Uncu, Turkey, Against: Luciano Nardo, UK</p> <p>Differed embryo transfer (DET) is bound to improve outcomes. Should we cryopreserve oocytes or embryos? TBA</p> <p>Subclinical hypothyroidism is a major cause of infertility in women: George J. Kahaly, Germany</p>
	<p>Origin of the stem cell types in the human ovary: Outi Hovatta, Sweden</p> <p>Germ line stem cells: Evelyn Telfer, UK</p> <p>Cross-border embryo transportation</p> <p>Cross-border transportation of fresh embryos: is it viable? Clinical overview: David Bider, Israel Laboratory overview: Jacob Levron, Israel</p>
15:30-16:00	<i>Coffee Break</i>
16:00-18:00	SESSION 7A: NEW INNOVATIONS IN BIOMARKERS DEVELOPMENT AND USE
	<p>AMH, FSH and AFC: can these markers guide us in cases of ovarian cysts and endometriosis surgery? Ludwig Kiesel, Germany</p> <p>Genomics, epigenomics, transcriptomics, proteomics and metabolomics: what should the focus in looking at the human endometrium? Jose Horcajadas, Spain</p> <p>G-CSF: does it add real value to IVF success? Norbert Gleicher, USA</p> <p>Mechanical irritation of the endometrium: is this the answer? Salim Daya, Canada</p>
	<p>IVM: finalizing the best protocol for the procedure: Seang Lin Tan, Canada</p> <p>"Burning out" PCOS patients: Norbert Gleicher, USA</p> <p>Optimal approach to adenomyosis and endometriosis treatment</p> <p>Adenomyosis: the optimal approach: Umit Inceboz, Turkey Is the vaginal mucosa the best route to administer steroids to treat endometriosis? Hugo Maia Jr, Brazil</p>

SATURDAY, MAY 16, 2015

08:30-10:30	SESSION 8: EMBRYO EVALUATION AND LUTEAL SUPPORT
	<p>The 3D embryo evaluation: a dream turned into a reality: Samir Hammaha, France</p> <p>Innovative luteal phase support: new options for enduring challenges</p> <p>Luteal phase support (LPS) is necessary in all forms of controlled ovarian stimulation (COS) cycles. What drugs are needed and how can they be delivered using better physiological methods: Dominique deZiegler, France</p> <p>Luteal phase support: dose ranging issues: Christian de Geyter, Switzerland</p> <p>Luteal coasting post GnRH agonist trigger: Shachar Kol, Israel</p>
10:30-11:00	<i>Coffee Break</i>
11:00-13:00	SESSION 9: INNOVATION IN TREATMENT PROTOCOLS
	<p>Debate: Natural cycle and minimal stimulation: is it a realistic approach or should it be abandoned? Pro: Thomas Strowitzki, Germany, Con: David Barad, USA</p> <p>Double stimulation: should this be a routine procedure in poor responders? Is it a possible solution? Dominique deZiegler, France</p> <p>Metformin: a treatment for all patients undergoing infertility treatment? David Barad, USA</p>